APOL1 Genotyping CTA Clinical Performance Study
A Prospective, Interventional Study to Assess the Clinical Performance of the APOL1 Genotyping Clinical Trial Assay in the Intended Use Population and Environment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Caoifa Dougan
- Phone Number: 00442838337575
- Email: ALDRegulatoryTeam@almacgroup.com
Study Contact Backup
- Name: Stewart McWilliams
- Phone Number: 00442838337575
- Email: ALDRegulatoryTeam@almacgroup.com
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27704
- Recruiting
- Almac Diagnostic Services LLC
-
Contact:
- Caoifa Dougan
- Phone Number: 00442838337575
- Email: ALDRegulatoryTeam@almacgroup.com
-
Principal Investigator:
- Richard Kennedy, MD PhD FRCP
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Study participants must be identified as a potential candidate for the pharmaceutical company- sponsored clinical trial by their physician based on the clinical trial inclusion criteria.
- Study participant has agreed to and signed the clinical trial Informed Consent Form (inclusive of risks related to the APOL1 Genotyping CTA).
- The study participant's specimen must be distributed to the device test site accompanied by a complete Test Request Form signed by the appropriate clinical trial site personnel.
- All participant specimens must meet predetermined specifications (e.g., undamaged, appropriate volume, appropriate specimen type, appropriate disease indication) for acceptance for testing by the device test site in accordance with established procedures.
Exclusion Criteria:
- Study participants will be excluded as a potential candidate for the pharmaceutical company -sponsored clinical trial by their physician based on the clinical trial exclusion criteria as assessed at screening visit 1.
- The study participant has not agreed to and signed the (Clinical Trial) Informed Consent Form.
- The study participant's specimen is distributed to the device test site without a complete Test Request Form.
- The study participant's specimen did not meet predetermined specifications for acceptance for testing by the device test site in accordance with established procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: APOL1 Genotyping
All study participants will submit a blood specimen for APOL1 Genotyping CTA screening.
The APOL1 Genotyping CTA will identify individuals who are homozygous or compound heterozygous for apolipoprotein L1 (APOL1) high-risk genotypes (G1 and G2).
The individuals who are identified as being homozygous or compound heterozygous for the APOL1 high-risk genotypes are candidates for enrolment onto an pharmaceutical company-sponsored, Phase 2b clinical trial which is investigating the safety and efficacy of a synthetic antisense oligonucleotide (ASO) for the treatment of APOL1-mediated kidney disease (AMKD).
|
The APOL1 Genotyping CTA will identify individuals who are homozygous or compound heterozygous for apolipoprotein L1 (APOL1) high-risk genotypes (G1 and G2).
The individuals who are identified as being homozygous or compound heterozygous for the APOL1 high-risk genotypes are candidates for enrolment onto an pharmaceutical company-sponsored, Phase 2b clinical trial which is investigating the safety and efficacy of a synthetic antisense oligonucleotide (ASO) for the treatment of APOL1-mediated kidney disease (AMKD).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of APOL1 genotype result within the study population (G1/G2/G0), for participants' specimens tested using the APOL1 Genotyping CTA
Time Frame: Through study completion, approximately 1 year
|
To utilize the APOL1 Genotyping CTA as a screening test to identify participants homozygous or compound heterozygous for high risk APOL1 genotypes (G1/G2) for inclusion in a Ph 2b trial
|
Through study completion, approximately 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of specimens submitted for APOL1 Genotyping CTA testing which meet device turn-around time (TAT)
Time Frame: Through study completion, approximately 1 year
|
To demonstrate with objective evidence how the APOL1 Genotyping CTA will be expected to perform in routine clinical practice
|
Through study completion, approximately 1 year
|
|
Percentage of specimens submitted for APOL1 Genotyping CTA testing which meet laboratory TAT
Time Frame: Through study completion, approximately 1 year
|
To demonstrate with objective evidence how the APOL1 Genotyping CTA will be expected to perform in routine clinical practice
|
Through study completion, approximately 1 year
|
|
Percentage of specimens submitted for APOL1 Genotyping CTA testing for which the device 'test was not ordered accurately (TNOA)
Time Frame: Through study completion, approximately 1 year
|
To demonstrate with objective evidence how the APOL1 Genotyping CTA will be expected to perform in routine clinical practice
|
Through study completion, approximately 1 year
|
|
Percentage 'Specimens Not Accepted (SNA)' by the clinical laboratory(ies) for APOL1 Genotyping CTA testing
Time Frame: Through study completion, approximately 1 year
|
To demonstrate with objective evidence how the APOL1 Genotyping CTA will be expected to perform in routine clinical practice
|
Through study completion, approximately 1 year
|
|
Percentage of Quality Control Failures
Time Frame: Through study completion, approximately 1 year
|
To demonstrate with objective evidence how the APOL1 Genotyping CTA will be expected to perform in routine clinical practice
|
Through study completion, approximately 1 year
|
|
Percentage of corrected reports
Time Frame: Through study completion, approximately 1 year
|
To demonstrate with objective evidence how the APOL1 Genotyping CTA will be expected to perform in routine clinical practice
|
Through study completion, approximately 1 year
|
|
Percentage of updated reports
Time Frame: Through study completion, approximately 1 year
|
To demonstrate with objective evidence how the APOL1 Genotyping CTA will be expected to perform in routine clinical practice
|
Through study completion, approximately 1 year
|
|
Percentage homozygous or compound heterozygous for APOL1 high risk genotypes within the study population
Time Frame: Through study completion, approximately 1 year
|
To determine the expected homozygous/ compound heterozygous APOL1 high risk genotype prevalence
|
Through study completion, approximately 1 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AE/SAE/ADE/UADE/SADE incident rate
Time Frame: Through study completion, approximately 1 year
|
Identification of AEs/ SAEs/ADE/UADE/SADE or complications associated with the APOL1 Genotyping CTA (participant and operator) inclusive of root cause identification (e.g., Device deficiency)
|
Through study completion, approximately 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Richard Kennedy, MD PhD FRCP, Almac Diagnostic Services Ltd
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SP2024001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.